- Home
- URGN vs MLTX Comparison
URGN vs MLTX Comparison
Compare URGN & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- MLTX
- Stock Information
- Founded
- URGN 2004
- MLTX 2021
- Country
- URGN United States
- MLTX Switzerland
- Employees
- URGN N/A
- MLTX N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- URGN Health Care
- MLTX Health Care
- Exchange
- URGN Nasdaq
- MLTX Nasdaq
- Market Cap
- URGN 1.1B
- MLTX 904.7M
- IPO Year
- URGN 2017
- MLTX N/A
- Fundamental
- Price
- URGN $27.39
- MLTX $13.38
- Analyst Decision
- URGN Strong Buy
- MLTX Buy
- Analyst Count
- URGN 8
- MLTX 9
- Target Price
- URGN $28.50
- MLTX $36.33
- AVG Volume (30 Days)
- URGN 1.4M
- MLTX 2.3M
- Earning Date
- URGN 11-06-2025
- MLTX 11-05-2025
- Dividend Yield
- URGN N/A
- MLTX N/A
- EPS Growth
- URGN N/A
- MLTX N/A
- EPS
- URGN N/A
- MLTX N/A
- Revenue
- URGN $96,516,000.00
- MLTX N/A
- Revenue This Year
- URGN $35.07
- MLTX N/A
- Revenue Next Year
- URGN $117.83
- MLTX N/A
- P/E Ratio
- URGN N/A
- MLTX N/A
- Revenue Growth
- URGN 8.00
- MLTX N/A
- 52 Week Low
- URGN $3.42
- MLTX $5.95
- 52 Week High
- URGN $27.98
- MLTX $62.75
- Technical
- Relative Strength Index (RSI)
- URGN 74.68
- MLTX 49.04
- Support Level
- URGN $24.69
- MLTX $12.43
- Resistance Level
- URGN $26.28
- MLTX $13.99
- Average True Range (ATR)
- URGN 1.87
- MLTX 0.75
- MACD
- URGN 0.32
- MLTX 0.85
- Stochastic Oscillator
- URGN 95.93
- MLTX 87.47
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.